Don’t wait for Angion Biomedica (NASDAQ GS: ANGN) to hit $100
I bought shares of ANGN and, if you want to take the proverbial trip “to the moon”, this Nasdaq biotech rocket ship is your ticket to ride.
Of course, you should perform further research and decide if this rocket ride is for you, but you probably already know that Biopharma stocks offer some of the best returns, when their products pass the FDA’s testing process. If you traded during the pandemic, you surely saw lots of biotechs skyrocket on FDA approval news.
Upcoming catalysts will bring the “smart” money into this stock, as the current ongoing trials come to their completion with expected results. ANGN’s been overlooked by all the Meme hype, but it’s one of the only stocks in an overbought market that still holds significant upside potential for anyone lucky enough to read this and get shares below the median analyst’s $40 target price.
The experts are projecting between a triple and going nearly 10 fold
- Stifel- “BUY” with a $40.00 Price Target
- Oppenheimer- “OUTPERFORM” and a 12-18 month Price Target of $38.00
- H.C. Wainwright “BUY” with a 12-month Price Target of $100 per share
The stock currently trades under $15, which means that, if the Suits or analysts are correct, ANGN should be an easy 100% gain for most people who buy under $20
Founded in 1998, Angion has spent more than $200 million developing its innovative technologies and they have significant cash on hand!
ANG-3777, its lead asset, is an hepatocyte growth factor (HGF) mimetic that enhances a pathway activated by the body’s response to injury. In other words, it’s a new way to address acute lung, kidney, and heart injuries, which are obviously very large markets and deeper clinical development for novel treatments means additional shots on goal – ANG-3070, a tyrokine kinase inhibitor (TKI), a ROCK2 inhibitor, and a CYP11B2 aldosterone synthase inhibitor.
Angion appears to represent a total paradigm shift for organ healing therapeutics.
With no currently approved treatments to prevent or reduce the severity of DGF and the U.S. Department of HHS wanting to double the number of kidney transplants, by 2030, ANG-3777’s potential to proactively accelerate the healthy repair process in cells may be the answer.
In addition to targeting the 3 most vital organs, there are numerous expansion possibilities, including spinal cord injuries and cerebral ischemia/stroke. Plus, on top of drastically improving the patient’s recovery experience, hospitals have over $5.4 Billion reasons (AKI’s estimated annual cost to hospitals, just in the U.S.) to swiftly adopt this type of disruptive solution. ANGN’s licensing agreement with Vifor Pharma, which generates $1.8 Billion in revenues and is one of the world’s most sophisticated nephrology (kidney) focused pharma firms, means that, upon therapy approval, we can expect to see the sales and usage ramp up very quickly.
Making money is always great; however, profiting from a company that may improve so many lives, by healing damaged hearts, kidney and lungs, is priceless. I’ve attached links for the analyst reports below.
Happy travels and let’s go to the moon.